Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
Verified emails & LinkedIn for founders across this portfolio.
Aardvark Therapeutics specializes in small molecule therapeutics for obesity and rare genetic metabolic disorders.
BBOT is a clinical-stage biopharmaceutical company advancing a pipeline of novel therapeutics targeting RAS and PI3K malignancies.
Synnovation Therapeutics is a precision oncology company that develops therapeutics that aims to help people with cancer.
Nexo Therapeutics offers treatments for some of cancer's most intractable targets.
Expansion Therapeutics is a biotechnology company focusing on developing transformative oral medicines for severe RNA-mediated diseases.
Monte Rosa Therapeutics is a biotechnology company that develops cancer therapeutics that modulate protein degradation pathways.
Alumis is a precision medicine company focused on the discovery, development and treatment of autoimmune disorders.
Praxis develops therapies for CNS disorders by leveraging genetic insights into neuronal imbalances, targeting rare to common conditions.
Wave Life Sciences is a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling diseases
Structure Therapeutics specializes in the discovery and development of drugs against a type of targets called GPCR.
Pliant Therapeutics focuses on discovering, developing, and commercializing breakthrough treatments for fibrotic diseases.
Longboard Pharmaceuticals delivers medicines with optimized pharmacology and pharmacokinetics to patients with rare neurological diseases.
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company.
Akura Medical is developing a next-generation thrombectomy device that aims to simplify thrombectomy through an easy-to-use.
nChroma Bio is a cutting-edge biotechnology business that is developing targeted in vivo delivery systems as well as best-in-class cargo.
BlossomHill Therapeutics is a biopharmaceutical company focusing on oncology and autoimmune disorders.
Umoja Biopharma is a biopharmaceutical company developing next-generation immunotherapies intended to combat cancer.
Verve Therapeutics is a clinical-stage biotechnology company developing genetic medicines for cardiovascular disease.
Replimune Group develop the next generation of ‘oncolytic immunotherapies’ for the treatment of cancer.
Shoreline Biosciences is a biomedical company intended to establish immunotherapies for seriously ill patients.
Aspen Neuroscience is a biotechnology company that specializes in personalized cell therapies and autologous regenerative medicine.
908devices manufactures battery-operated, hand-held chemical detection tools used in mass spectrometry.
Biomea Fusion is a precision oncology company developing novel small molecules that target aggressive forms of cancer.
Averto Medical is a medical device manufacturing company.
Cormorant Asset Management has invested in 209 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Cormorant Asset Management's top investment sectors include Biotechnology, Health Care, Medical, Therapeutics, Pharmaceutical. The firm invests across 21 different industry categories.
Among tracked funding rounds, Structure Therapeutics received $747.5M in a Post-IPO Equity round. Cormorant Asset Management's total known invested capital is $23.5B.
Cormorant Asset Management's average investment size is $137.2M across its portfolio of 209 companies.
Recent Cormorant Asset Management portfolio additions include Aardvark Therapeutics, BBOT, Synnovation Therapeutics, Nexo Therapeutics, Expansion Therapeutics. These companies were founded in 2020 or later.